Anti-leukemic properties of IL-12, IL-23 and IL-27: differences and similarities in the control of pediatric B acute lymphoblastic leukemia

Crit Rev Oncol Hematol. 2012 Sep;83(3):310-8. doi: 10.1016/j.critrevonc.2011.11.006. Epub 2011 Dec 15.

Abstract

B acute lymphoblastic leukemia (ALL) is the most common pediatric hematologic malignancy. Although patient cure has reached an excellent rate, a minority of cases relapse and need novel therapies. IL-12, IL-23 and IL-27 belong to the IL-12 superfamily and exert immunological and anti-tumor functions. The latter can be mediated by activation of immune responses or by the direct activity on cancer cells. Recently, the role of IL-12, IL-23 and IL-27 in the control of pediatric B-ALL has been unveiled. Here, we discuss in a translational perspective the role of IL-12 family cytokines in pediatric B-ALL, highlighting similarities and differences in their mechanisms of action.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Interleukin-12 / immunology
  • Interleukin-12 / therapeutic use*
  • Interleukin-23 / immunology
  • Interleukin-23 / therapeutic use*
  • Interleukins / immunology
  • Interleukins / therapeutic use*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology

Substances

  • Antineoplastic Agents
  • Interleukin-23
  • Interleukins
  • MYDGF protein, human
  • Interleukin-12